FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4365514056> ?p ?o ?g. }

• W4365514056 endingPage "CT028" @default.
• W4365514056 startingPage "CT028" @default.
• W4365514056 abstract "Abstract Background: Mutations in KRAS are among the most frequent oncogenic drivers with the G12C mutation found in up to ~13% of NSCLC. LY3537982 is an oral, highly selective, and potent inhibitor of KRAS G12C, which preclinically delivers &gt;90% sustained target occupancy. We present the initial results from LOXO-RAS-20001, a phase 1 study of LY3537982 in patients (pts) with KRAS G12C-mutant advanced solid tumors (NCT04956640). Methods: LY3537982 monotherapy dose escalation followed a mTPI-2 method. Dose expansion cohorts included combinations with pembrolizumab (NSCLC) and cetuximab (CRC). Key objectives were to determine the RP2D of LY3537982, safety, PK, and antitumor activity per RECIST v1.1. Results: As of 17 August 2022, 56 pts with NSCLC (16), CRC (17), PANC (8), and other tumor types (15) were treated with LY3537982 monotherapy on doses from 50-200 mg BID. Median number of prior systemic therapies was 2 (range, 0-8). No DLTs were observed, MTD was not reached, and RP2D determination is ongoing. Median time on treatment was 3 months (range, 0.3-13), 33 pts are ongoing, and 23 pts discontinued (none due to a related AE). TEAEs observed in ≥10% of pts were diarrhea (38%), constipation (16%), fatigue (16%), peripheral oedema (13%), and nausea (11%), mostly grade 1. The only grade ≥3 treatment related AE was neutropenia (n=1), and no pneumonitis or grade ≥2 transaminitis was observed. There were no treatment related serious AEs or deaths. Dose proportional steady-state exposures were observed through 150 mg BID. Table shows preliminary efficacy data. Conclusions: LY3537982 demonstrated a favorable safety profile, including the absence of high-grade liver toxicity, and tolerance in pts previously intolerant to other KRAS G12C inhibitors. Preliminary efficacy was observed with LY3537982 monotherapy across multiple tumor types. Updated data in more than 100 pts, including data in combination with pembrolizumab and cetuximab will be presented. Table: Preliminary LY3537982 Monotherapy Efficacy NSCLC (KRAS G12Ci naïve)(N=5) NSCLC(Prior KRAS G12Ci treated) (N=11) CRCd(N=17) PANCd(N=8) Other tumor typesd,f(N=15) Efficacy Evaluablea, n 5 9 15 8 11 ORR, n (%) 3 (60%) 0 1 (7%) 3 (38%) 4 (36%) BOR, n (%) PR, n (%) 3 (60%)c 0 1 (7%)e 3 (38%)e 4 (36%)g SD, n (%) 1 (20%) 6 (67%) 13 (87%) 4 (50%) 6 (55%) PD, n (%) 1 (20%) 3 (33%) 1 (7%) 1 (13%) 1 (9%) DCRb, n (%) 4 (80%) 6 (67%) 14 (93%) 7 (88%) 10 (91%) Abbreviations: CRC, colorectal cancer; NSCLC, non-small cell lung cancer; PANC, pancreatic cancer aEfficacy evaluable pts are those who had at least one post-baseline response assessment or had discontinued treatment bDCR includes PR+SD c3 NSCLC pts have unconfirmed PRs, ongoing and pending confirmation as of the data cut-off date dAll pts KRAS G12C inhibitor naïve, prior KRAS G12C inhibitor therapy not permitted for tumor types other than NSCLC e1 CRC pt and 1 PANC pt have unconfirmed PR, ongoing and pending confirmation as of the data cut-off date fOther tumor types include cholangiocarcinoma (n=4), chondrosarcoma (n=1), jejunal adenocarcinoma (n=1), large cell neuroendocrine of lung (n=1), nasal malignant melanoma (n=1), ovarian cancer (n=3), salivary adenoid cystic carcinoma (n=1), small intestine cancer (n=1), tracheal basaloid squamous cell carcinoma (n=1), and upper tract urothelial carcinoma (n=1) gPRs observed in pts with tracheal basaloid squamous cell carcinoma, cholangiocarcinoma, nasal malignant melanoma, and ovarian cancer (1 each) Citation Format: Yonina R. Murciano-Goroff, Rebecca S. Heist, Yasutoshi Kuboki, Takafumi Koyama, Natraj Reddy Ammakkanavar, Antoine Hollebecque, Amita Patnaik, Toshio Shimizu, Alexander I. Spira, Misako Nagasaka, Ji-Youn Han, Wade Thomas Iams, Dustin Deming, Justin Call, Philippe Cassier, Sae-Won Han, Quincy Siu-chung Chu, Rasha Cosman, Gregory Durm, Timothy Burns, Melinda D. Willard, Shiyao Liu, Sophie Callies, Arjun V. Balar, Joshua K. Sabari. A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 2 (Clinical Trials and Late-Breaking Research); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(8_Suppl):Abstract nr CT028." @default.
• W4365514056 created "2023-04-15" @default.
• W4365514056 creator A5004964053 @default.
• W4365514056 creator A5018378822 @default.
• W4365514056 creator A5021421417 @default.
• W4365514056 creator A5023055777 @default.
• W4365514056 creator A5024203424 @default.
• W4365514056 creator A5027371764 @default.
• W4365514056 creator A5034270737 @default.
• W4365514056 creator A5036139118 @default.
• W4365514056 creator A5041593880 @default.
• W4365514056 creator A5043862738 @default.
• W4365514056 creator A5044613951 @default.
• W4365514056 creator A5046628885 @default.
• W4365514056 creator A5048019436 @default.
• W4365514056 creator A5051346978 @default.
• W4365514056 creator A5052823826 @default.
• W4365514056 creator A5053257668 @default.
• W4365514056 creator A5054876338 @default.
• W4365514056 creator A5064382279 @default.
• W4365514056 creator A5069294598 @default.
• W4365514056 creator A5070570779 @default.
• W4365514056 creator A5071418777 @default.
• W4365514056 creator A5072635753 @default.
• W4365514056 creator A5073605756 @default.
• W4365514056 creator A5079993897 @default.
• W4365514056 creator A5086593040 @default.
• W4365514056 date "2023-04-14" @default.
• W4365514056 modified "2023-10-03" @default.
• W4365514056 title "Abstract CT028: A first-in-human phase 1 study of LY3537982, a highly selective and potent KRAS G12C inhibitor in patients with KRAS G12C-mutant advanced solid tumors" @default.
• W4365514056 doi "https://doi.org/10.1158/1538-7445.am2023-ct028" @default.
• W4365514056 hasPublicationYear "2023" @default.
• W4365514056 type Work @default.
• W4365514056 citedByCount "3" @default.
• W4365514056 countsByYear W43655140562023 @default.
• W4365514056 crossrefType "journal-article" @default.
• W4365514056 hasAuthorship W4365514056A5004964053 @default.
• W4365514056 hasAuthorship W4365514056A5018378822 @default.
• W4365514056 hasAuthorship W4365514056A5021421417 @default.
• W4365514056 hasAuthorship W4365514056A5023055777 @default.
• W4365514056 hasAuthorship W4365514056A5024203424 @default.
• W4365514056 hasAuthorship W4365514056A5027371764 @default.
• W4365514056 hasAuthorship W4365514056A5034270737 @default.
• W4365514056 hasAuthorship W4365514056A5036139118 @default.
• W4365514056 hasAuthorship W4365514056A5041593880 @default.
• W4365514056 hasAuthorship W4365514056A5043862738 @default.
• W4365514056 hasAuthorship W4365514056A5044613951 @default.
• W4365514056 hasAuthorship W4365514056A5046628885 @default.
• W4365514056 hasAuthorship W4365514056A5048019436 @default.
• W4365514056 hasAuthorship W4365514056A5051346978 @default.
• W4365514056 hasAuthorship W4365514056A5052823826 @default.
• W4365514056 hasAuthorship W4365514056A5053257668 @default.
• W4365514056 hasAuthorship W4365514056A5054876338 @default.
• W4365514056 hasAuthorship W4365514056A5064382279 @default.
• W4365514056 hasAuthorship W4365514056A5069294598 @default.
• W4365514056 hasAuthorship W4365514056A5070570779 @default.
• W4365514056 hasAuthorship W4365514056A5071418777 @default.
• W4365514056 hasAuthorship W4365514056A5072635753 @default.
• W4365514056 hasAuthorship W4365514056A5073605756 @default.
• W4365514056 hasAuthorship W4365514056A5079993897 @default.
• W4365514056 hasAuthorship W4365514056A5086593040 @default.
• W4365514056 hasConcept C121608353 @default.
• W4365514056 hasConcept C126322002 @default.
• W4365514056 hasConcept C143998085 @default.
• W4365514056 hasConcept C197934379 @default.
• W4365514056 hasConcept C2777063308 @default.
• W4365514056 hasConcept C2779998722 @default.
• W4365514056 hasConcept C2780580376 @default.
• W4365514056 hasConcept C2781187634 @default.
• W4365514056 hasConcept C29730261 @default.
• W4365514056 hasConcept C526805850 @default.
• W4365514056 hasConcept C71924100 @default.
• W4365514056 hasConcept C90924648 @default.
• W4365514056 hasConceptScore W4365514056C121608353 @default.
• W4365514056 hasConceptScore W4365514056C126322002 @default.
• W4365514056 hasConceptScore W4365514056C143998085 @default.
• W4365514056 hasConceptScore W4365514056C197934379 @default.
• W4365514056 hasConceptScore W4365514056C2777063308 @default.
• W4365514056 hasConceptScore W4365514056C2779998722 @default.
• W4365514056 hasConceptScore W4365514056C2780580376 @default.
• W4365514056 hasConceptScore W4365514056C2781187634 @default.
• W4365514056 hasConceptScore W4365514056C29730261 @default.
• W4365514056 hasConceptScore W4365514056C526805850 @default.
• W4365514056 hasConceptScore W4365514056C71924100 @default.
• W4365514056 hasConceptScore W4365514056C90924648 @default.
• W4365514056 hasIssue "8_Supplement" @default.
• W4365514056 hasLocation W43655140561 @default.
• W4365514056 hasOpenAccess W4365514056 @default.
• W4365514056 hasPrimaryLocation W43655140561 @default.
• W4365514056 hasRelatedWork W2004525065 @default.
• W4365514056 hasRelatedWork W2006527196 @default.
• W4365514056 hasRelatedWork W2049754458 @default.
• W4365514056 hasRelatedWork W2313360580 @default.
• W4365514056 hasRelatedWork W2321720825 @default.
• W4365514056 hasRelatedWork W2566317011 @default.
• W4365514056 hasRelatedWork W2803208177 @default.
• W4365514056 hasRelatedWork W2889779047 @default.
• W4365514056 hasRelatedWork W3026015583 @default.

• next